{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:24:28Z","timestamp":1787628268090,"version":"build-2736575974"},"reference-count":105,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers. Giant cells are multinucleated epithelioid cells derived from macrophages. Histologically, giant cells are also present in other pathologies of bone, e.g., aneurysmal bone cyst, chondroblastoma, giant cell granuloma, and malignant giant cell tumor, etc. Similarly, radiographic findings overlap with other osteolytic lesions, making the diagnosis and prognosis of giant cell tumor very challenging. Aims and Objectives: The purpose of this study was to explore biological and genetic markers which can be used for detection, differentiation, recurrence, and prognosis of GCTB. This will help to better understand the clinical outcome of GCTB and minimize the need for interventions. Methods: We conducted a literature search using Google, Google Scholar, PubMed, Wiley Library, Medline, Clinical trials.org, and Web of Science. Our search strategy included MeSH terms and key words for giant cell tumor and biogenetic markers from date of inception to September 2020. After excluding review articles, 246 duplicates, and non-relevant articles, we included 24 articles out of 1568 articles, summarizing the role of biogenetic markers in the prognosis of GCT. Results: P63 is 98.6% sensitive and relatively specific for GCT as compared to other multinucleated giant cells containing neoplasms. MDM2 (mouse double minute 2 homolog), IGF1 (insulin-like growth factor 1), STAT1 (signal transducer and activator of transcription 1), and RAC1 (Ras-related C3 botulinum toxin substrate 1) are associated with GCTB recurrence, and might serve as biomarkers for it. Increased expression of the proteins STAT5B, GRB2, and OXSR1 was related to a higher probability of metastasis. H3F3A and H3F3B mutation analysis appears to be a highly specific, although less sensitive, diagnostic tool for the distinction of giant cell tumor of bone (GCTB) and chondroblastoma from other giant cell-containing tumors. A neutrophil to lymphocyte ratio (NLR) &gt; 2.70, platelet to lymphocyte ratio (PLR) &gt; 215.80, lymphocyte to monocyte ratio (LMR) \u2264 2.80, and albumin to globulin ratio (AGR) &lt; 1.50 were significantly associated with decreased disease-free survival (DFS) (p &lt; 0.05). Large amounts of osteoclast-related mRNA (cathepsin K, tartrate-resistant acid phosphatase, and matrix metalloproteinase9) in GCTs (p &lt; 0.05) are associated with the grade of bone resorption. We propose that subarticular primary malignant bone sarcomas with H3.3 mutations represent true malignant GCTB, even in the absence of a benign GCTB component. IMP3 and IGF2 might be potential biomarkers for GCT of the spine in regulating the angiogenesis of giant cell tumor of bone and predicting patients\u2019 prognosis. Conclusions: This review study shows serological markers, genetic factors, cell membrane receptor markers, predictive markers for malignancy, and prognostic protein markers which are highly sensitive for GCT and relatively specific for giant cell tumor. MDM2, IGF1, STAT1, RAC1 are important makers in determining recurrence, while P63 and H3F3A differentiate GCT from other giant cell-containing tumors. STAT5B, GRB2, and OXSR1 are significant in determining the prognosis of GCT. Apart from using radiological and histological parameters, we can add them to tumor work-up for definitive diagnosis and prognosis.<\/jats:p>","DOI":"10.3390\/diagnostics15010039","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T09:13:32Z","timestamp":1735290812000},"page":"39","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Muhammad","family":"Taqi","sequence":"first","affiliation":[{"name":"Orthopedic Surgery, Macquarie University Hospital, Sydney, NSW 2113, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0304-3378","authenticated-orcid":false,"given":"Haseeb","family":"ul Rasool","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Icahn School of Medicine Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobeen","family":"Zaka Haider","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Carle Foundation Hospital, Urbana, IL 61801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munjed","family":"Al Muderis","sequence":"additional","affiliation":[{"name":"Orthopedic Surgery, Macquarie University Hospital, Sydney, NSW 2113, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5435\/JAAOS-21-02-118","article-title":"Giant cell tumor of bone","volume":"21","author":"Raskin","year":"2013","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_2","first-page":"2","article-title":"Giant Cell Tumor of Bone\u2014An Overview","volume":"4","author":"Sobti","year":"2016","journal-title":"Arch. Bone Jt. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ocl.2005.08.005","article-title":"Giant cell tumor of bone","volume":"37","author":"Turcotte","year":"2006","journal-title":"Orthop. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00003086-198812000-00040","article-title":"Giant-cell tumor of bone with pulmonary metastases. Six case reports and a review of the literature","volume":"237","author":"Bertoni","year":"1988","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1302\/0301-620X.80B1.0800043","article-title":"Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up","volume":"80","author":"Siebenrock","year":"1998","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_6","first-page":"618","article-title":"Giant cell tumor of bone in children and adolescents","volume":"63","author":"Hoeffel","year":"1996","journal-title":"Rev. Rhum. Engl. Ed."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40946","DOI":"10.18632\/oncotarget.16784","article-title":"Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma","volume":"8","author":"Meaney","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00256-015-2117-5","article-title":"Giant cell tumor: Rapid recurrence after cessation of long-term denosumab therapy","volume":"44","author":"Matcuk","year":"2015","journal-title":"Skelet. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12094-014-1268-5","article-title":"Giant cell tumour of bone: New treatments in development","volume":"17","author":"Garrido","year":"2015","journal-title":"Clin. Transl. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.joms.2008.12.045","article-title":"CD34 staining density predicts giant cell tumor clinical behavior, American Association of Oral and Maxillofacial Surgeons","volume":"67","author":"Susarla","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12957-015-0579-5","article-title":"Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance","volume":"13","author":"Zhang","year":"2015","journal-title":"World J. Surg. Oncol."},{"key":"ref_12","first-page":"656","article-title":"CD147 expression as a recurrence and metastatic marker in giant cell tumor of the bone","volume":"182","author":"Miskad","year":"2023","journal-title":"Gazz. Medica Ital. Arch. Sci. Mediche"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajpath.2010.11.035","article-title":"Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis","volume":"178","author":"Conti","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Scotto di Carlo, F., Divisato, G., Iacoangeli, M., Esposito, T., and Gianfrancesco, F. (2018). The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4291-z"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.jbo.2021.100354","article-title":"Prediction of the early recurrence in spinal giant cell tumor of bone using radiomics of preoperative CT: Long-term outcome of 62 consecutive patients","volume":"27","author":"Wang","year":"2021","journal-title":"J. Bone Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/0278-2391(86)90040-6","article-title":"Central giant cell lesions of the jaws: A clinicopathologic study","volume":"44","author":"Chuong","year":"1986","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.joms.2008.01.033","article-title":"Immunohistochemical evaluation of giant cell tumors of the jaws using CD34 density analysis","volume":"66","author":"Dewsnup","year":"2008","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tripleo.2005.02.060","article-title":"Central giant cell granuloma of the jaws: A clinical, radiologic, and histopathologic study of 26 cases","volume":"101","author":"DialloZ","year":"2006","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0030-4220(88)90094-1","article-title":"A clinical and histomorphologic comparison of the central giant cell granuloma and the giant cell tumor","volume":"66","author":"Auclair","year":"1988","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ajcp\/45.4.437","article-title":"The central giant cell reparative granuloma of the jaws: An analysis of 38 cases","volume":"45","author":"Waldron","year":"1966","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0278-2391(88)90221-2","article-title":"Central giant cell granuloma of the jaws: Experiences in the management of thirty-seven cases","volume":"46","author":"Eisenbud","year":"1988","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0266-4356(95)90086-1","article-title":"Central giant cell granuloma of jaws\u2014Review of 19 cases","volume":"33","author":"Sidhu","year":"1995","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e17445","DOI":"10.1097\/MD.0000000000017445","article-title":"Plasma metabolite profiling reveals potential biomarkers of giant cell tumor of bone by using NMR-based metabolic profiles: A cross-sectional study","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrd1157","article-title":"Opinion: Understanding \u2018global\u2019 systems biology: Metabonomics and the continuum of metabolism","volume":"2","author":"Nicholson","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"M110.004945","DOI":"10.1074\/mcp.M110.004945","article-title":"Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma","volume":"10","author":"Chen","year":"2011","journal-title":"Mol. Cell. Proteom."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1248\/yakushi.131.1305","article-title":"Mass spectrometry-based quantitative analysis and biomarker discovery","volume":"131","author":"Suzuki","year":"2011","journal-title":"J. Pharm. Soc. Jpn."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jpba.2014.12.020","article-title":"Emerging field of metabolomics: Big promise for cancer biomarker identification and drug discovery","volume":"107","author":"Patel","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s00259-011-1786-0","article-title":"Molecular imaging of microRNAs","volume":"38","author":"Wang","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mangolini, A., Ferracin, M., Zanzi, M.V., Saccenti, E., Ebnaof, S.O., Poma, V.V., Sanz, J.M., Passaro, A., Pedriali, M., and Frassoldati, A. (2015). Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomark. Res., 3.","DOI":"10.1186\/s40364-015-0037-0"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs\u2014microRNAs with a role in cancer","volume":"6","author":"Slack","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbrc.2014.09.076","article-title":"MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone","volume":"453","author":"Huang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbrc.2013.12.075","article-title":"MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13","volume":"443","author":"Wu","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/os.12231","article-title":"Characterization of MicroRNA Expression Profiles in Patients with Giant Cell Tumor","volume":"8","author":"Qin","year":"2016","journal-title":"Orthop. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.biocel.2007.02.012","article-title":"Ezrin\/radixin\/moesin: Versatile controllers of signalling molecules and of the cortical cytoskeleton","volume":"40","author":"Niggli","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/ijc.24216","article-title":"Roles of ezrin in the growth and invasiveness of esophageal squamous carcinoma cells","volume":"124","author":"Xie","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/onc.2008.437","article-title":"The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC","volume":"28","author":"Ren","year":"2009","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"R365","DOI":"10.1186\/bcr1006","article-title":"The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells","volume":"7","author":"Elliott","year":"2005","journal-title":"Breast Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0090-8258(03)00262-2","article-title":"Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients","volume":"90","author":"Moilanen","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Yeh, C.N., Pang, S.T., Chen, T.W., Wu, R.C., Weng, W.H., and Chen, M.F. (2009). Expression of Ezrin is associated with invasion and dedifferentiation of hepatitis B related hepatocellular carcinoma. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-233"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/modpathol.2010.77","article-title":"Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell","volume":"23","author":"Leopizzi","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.prp.2010.10.005","article-title":"CD147 (EMMPRIN) and matrix metalloproteinase-2 expression in uterine endometrioid adenocarcinoma","volume":"207","author":"Stewart","year":"2011","journal-title":"Pathol. Res. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suronc.2009.09.002","article-title":"VEGF and EMMPRIN expression correlates with survival of atients with osteosarcoma","volume":"20","author":"Zhou","year":"2011","journal-title":"Surg. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-0774.2003.tb00123.x","article-title":"Role of cancer cell-stroma interaction in invasive growth of cancer cells","volume":"16","author":"Kataoka","year":"2003","journal-title":"Hum. Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1440-1827.2006.01972.x","article-title":"Emmprin (basigin\/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression","volume":"56","author":"Nabeshima","year":"2006","journal-title":"Pathol. Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.yexmp.2007.08.014","article-title":"CD147 immunoglobulin superfamily receptor function and role in pathology","volume":"83","author":"Iacono","year":"2007","journal-title":"Exp. Mol. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2249.2010.04115.x","article-title":"Cyclophilin-CD147 interactions: A new target for anti-inflammatory therapeutics","volume":"160","author":"Yurchenko","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/bbrc.1996.0980","article-title":"Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and blood-brain barrier","volume":"224","author":"Igakura","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12307-012-0116-9","article-title":"Role of p63 in Development, Tumorigenesis and Cancer Progression","volume":"5","author":"Bergholz","year":"2012","journal-title":"Cancer Microenviron."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/modpathol.2008.29","article-title":"Giant cell tumor of bone express p63","volume":"21","author":"Dickson","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1746-1596-7-130","article-title":"Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan Experience","volume":"7","author":"Hammas","year":"2012","journal-title":"Diagn. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/03009734.2012.724731","article-title":"p63 as a prognostic marker for giant cell tumor of bone","volume":"118","author":"Yanagisawa","year":"2013","journal-title":"Upsala J. Med. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1159\/000430164","article-title":"Factors Affecting the Recurrence of Giant Cell Tumor of Bone","volume":"36","author":"Cheng","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5114\/pjp.2015.57252","article-title":"Prognostic value of p53 protein expression in giant cell tumor of bone","volume":"66","author":"Yalcinkaya","year":"2015","journal-title":"Pol. J. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1091\/mbc.e10-07-0571","article-title":"Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling","volume":"22","author":"Watkins","year":"2011","journal-title":"Mol. Biol. Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1302\/0301-620X.86B1.14053","article-title":"Giant-cell tumour of bone","volume":"86","author":"Szendroi","year":"2004","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.humpath.2005.07.005","article-title":"Phenotypic and molecular studies of giant cell tumors of bone and soft tissue","volume":"36","author":"Lau","year":"2005","journal-title":"Hum. Pathol."},{"key":"ref_61","first-page":"337","article-title":"Canonical and non-canonical pathways of osteoclast formation","volume":"24","author":"Knowles","year":"2009","journal-title":"Histol. Histopathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0002-9440(10)63323-8","article-title":"Cathepsin K is the principal protease in giant cell tumor of bone","volume":"165","author":"Lindeman","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1359\/jbmr.080905","article-title":"CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone","volume":"24","author":"Forsyth","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1084\/jem.20041785","article-title":"Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis","volume":"201","author":"Annels","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/1097-0142(19940815)74:4<1253::AID-CNCR2820740412>3.0.CO;2-9","article-title":"Conservative surgery for giant cell tumors of sacrum. The role of cryosurgery as a supplement to curettage and partial excision","volume":"74","author":"Marcove","year":"1994","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1245\/s10434-009-0803-z","article-title":"Primary malignant giant-cell tumor of bone has high survival rate","volume":"17","author":"Domovitov","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00432-008-0370-x","article-title":"Giant cell tumor of bone: Treatment and outcome of 214 cases","volume":"134","author":"Balke","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002640050381","article-title":"The prognostic significance of DNA cytophotometry and proliferation index (Ki-67) in giant cell tumors of bone","volume":"23","author":"Antal","year":"1999","journal-title":"Int. Orthop."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1756-9966-29-25","article-title":"Ki-67 immuno-histochemistry index in stage III giant cell tumor of the bone","volume":"29","author":"Ismail","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_70","first-page":"79","article-title":"Metachronous multicentric giant-cell tumor of the bone in the lower limb. Case report and Ki-67 immunohistochemistry study","volume":"445","author":"Rousseau","year":"2004","journal-title":"Virchows Arch."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.MP.0000057235.65327.40","article-title":"Cyclin alterations in giant cell tumor of bone","volume":"16","author":"Kauzman","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.prp.2011.07.009","article-title":"A case of de novo secondary malignant giant-cell tumor of bone with loss of heterozygosity of p53 gene that transformed within a short-term follow-up","volume":"207","author":"Saito","year":"2011","journal-title":"Pathol. Res. Pract."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Balke, M., Campanacci, L., Gebert, C., Picci, P., Gibbons, M., Taylor, R., Hogendoorn, P., Kroep, J., Wass, J., and Athanasou, N. (2010). Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-462"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/362857a0","article-title":"Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53","volume":"362","author":"Oliner","year":"1993","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","article-title":"A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans","volume":"119","author":"Bond","year":"2004","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"22654","DOI":"10.1074\/jbc.M111.279091","article-title":"Inhibition of Insulin-like Growth Factor-1 (IGF-1) Expression by Prolonged Transforming Growth Factor-\u03b21 (TGF-\u03b21) Administration Suppresses Osteoblast Differentiation","volume":"287","author":"Ochiai","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1038\/sj.onc.1204086","article-title":"STAT proteins: Novel molecular targets for cancer drug discovery","volume":"19","author":"Turkson","year":"2000","journal-title":"Oncogene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cge.12908","article-title":"Emerging roles of RAC1in treating lung cancer patients","volume":"91","author":"Zou","year":"2017","journal-title":"Clin. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/104303404322886093","article-title":"Redox regulation of pancreatic cancer cell growth: Role of glutathione peroxidase in the suppression of the malignant phenotype","volume":"15","author":"Liu","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_80","first-page":"2085","article-title":"Overexpression of peroxiredoxin in human breast cancer","volume":"21","author":"Noh","year":"2001","journal-title":"Anticancer. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"13870","DOI":"10.1073\/pnas.1414358111","article-title":"Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade","volume":"111","author":"Wu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/13894501113146660230","article-title":"Hsp27 as a therapeutic target in cancers","volume":"15","author":"Acunzo","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e1800041","DOI":"10.1002\/prca.201800041","article-title":"Circulating Candidate Biomarkers in Giant Cell Tumors of Bone","volume":"12","author":"Conti","year":"2018","journal-title":"Proteom. Clin. Appl."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/pmic.201500164","article-title":"Identification of novel candidate circulating biomarkers for malignant soft tissue sarcomas","volume":"16","author":"Conti","year":"2016","journal-title":"Proteomics"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of proteomic patterns in serum to identify ovarian cancer","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00006676-200201000-00002","article-title":"Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide","volume":"24","author":"Basso","year":"2002","journal-title":"Pancreas"},{"key":"ref_87","first-page":"28","article-title":"A rapid protein profiling system that speeds study of cancer and other diseases","volume":"19","author":"Rubin","year":"2000","journal-title":"Am. Clin. Lab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12094-015-1280-4","article-title":"Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis","volume":"17","author":"Zhang","year":"2015","journal-title":"Clin. Transl. Oncol."},{"key":"ref_89","first-page":"4697","article-title":"IL-17A Stimulates the Progression of Giant Cell Tumors of Bone","volume":"19","author":"Xu","year":"2013","journal-title":"Hum. Cancer Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"86934","DOI":"10.18632\/oncotarget.21168","article-title":"Nomograms for prognostic factors of spinal giant cell tumor combining traditional clinical characteristics with inflammatory biomarkers after gross total resection","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1097\/PAS.0000000000000512","article-title":"Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma","volume":"39","author":"Cleven","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"776","DOI":"10.5858\/2010-0291-OA.1","article-title":"p63 expression in giant cell-containing lesions of bone and soft tissue","volume":"135","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.prp.2016.07.007","article-title":"P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions","volume":"212","author":"Shooshtarizadeh","year":"2016","journal-title":"Pathol. Res. Pract."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-014-1666-7","article-title":"Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis","volume":"465","author":"Lieveld","year":"2014","journal-title":"Virchows Arch."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4564328","DOI":"10.1155\/2018\/4564328","article-title":"STAT1, IGF1, RAC1, and MDM2 Are Associated with Recurrence of Giant Cell Tumor of Bone","volume":"2018","author":"Chen","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/PAS.0000000000000859","article-title":"H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone","volume":"41","author":"Amary","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cncy.22000","article-title":"Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy","volume":"126","author":"Schaefer","year":"2018","journal-title":"Cancer Cytopathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.humpath.2017.08.033","article-title":"Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone","volume":"68","author":"Righi","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Balla, P., Maros, M.E., Barna, G., Antal, I., Papp, G., Sapi, Z., Athanasou, N.A., Benassi, M.S., Picci, P., and Krenacs, T. (2015). Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125316"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00300442","article-title":"Secretion of matrix metalloproteinase-2 (72 kD gelatinase\/type IV collagenase = gelatinase A) by malignant human glioma cell lines: Implications for the growth and cellular invasion of the extracellular matrix","volume":"28","author":"Nakagawa","year":"1996","journal-title":"J. Neuro-Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.blo.0000160024.06739.ff","article-title":"Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?","volume":"435","author":"Prosser","year":"2005","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_102","first-page":"8446","article-title":"Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bones","volume":"8","author":"Han","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00428-013-1435-z","article-title":"p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1","volume":"463","author":"Okubo","year":"2013","journal-title":"Virchows Arch."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13691-013-0142-6","article-title":"Giant-cell tumor of bone arising in the anterior rib with a positive expression of GPX-1: A case report and review of the literature","volume":"3","author":"Toda","year":"2014","journal-title":"Int. Cancer Conf. J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2119\/molmed.2015.00183","article-title":"Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges","volume":"21","author":"Singh","year":"2015","journal-title":"Mol. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/1\/39\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:01:22Z","timestamp":1760115682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/1\/39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["diagnostics15010039"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15010039","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}